Table 1.
Baseline characteristics.
Table 2.
Interventions and events during index hospitalisation.
Table 3.
Therapy at discharge and premature discontinuation of TAT.
Fig 1.
Long term risk of bleeding in patients discharged with triple antithrombotic therapy.
Log rank test men vs women 0.09.
Table 4.
Bleeding and ischemic events during follow-up.
Table 5.
Unit costs and one-year health care costs in bleeders and non-bleeders, EUR, Euro.